Regado Biosciences develops antithrombotic aptamers paired with active control agents, including clinical candidates REG1 and REG3. The company is advancing REG1 toward a Phase 3 study called REGULATE – PCI for use in percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) population. It is also pursuing a parallel development program of REG1 for transaortic valve implantation (TAVI) and a program for REG3 in diabetic vasculopathy. Regado recently secured $51m in Series E financing to support these programs. The company is led by President and CEO David J. Mazzo, PhD, and is based in Basking Ridge, New Jersey, with a lab facility in Durham, North Carolina. Regado Biosciences, based in Basking Ridge, NJ, focuses on a new therapeutic technology applied to injectable antithrombotics. The company is developing a pipeline of programs targeting arterial and venous thrombosis. It is also working to identify therapeutic aptamers as clinical candidates. Regado completed a $40M Series D financing to support these efforts. The round was led by Edmond de Rothschild Investment Partners (part of The LCF Rothschild Group) and included participation from Domain Associates, Quaker Bioventures, Aurora Funds, Caxton Advantage Life Sciences Fund and other individual investors. Proceeds will be used to continue development of its thrombosis programs and to advance identification of a clinical aptamer candidate.

Total raised

$91M

Funding rounds

2

Latest round

Series E

Latest activity

Dec 2012